Publications

Papp-Wallace KM, Shapiro AB, Becka SA, Zeiser ET, LiPuma JJ, Lane DJ, Panchal RG, Mueller JP, O'Donnell JP, and Miller AA

In vitro activity and in vivo efficacy of sulbactam-durlobactam against pathogenic Burkholderia species

Antimicrobial Agents and Chemotherapy (2021)

Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP and Rice PA

Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)

Antimicrobial Agents and Chemotherapy (2021)

Shapiro AB and Gao N

Interactions of the diazabicyclooctane serine β-lactamase inhibitor ETX1317 with target enzymes

ACS Infectious Diseases (2020)

Shapiro AB, Moussa SH, Carter NM, Gao N, and Miller AA

Ceftazidime-avibactam resistance mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-lactamase do not alter cefpodoxime-ETX1317 susceptibility 

ACS Infectious Diseases (2020)

Furuya T, Shapiro AB, Comita-Prevoir J, Kuenstner EJ, Zhang J, Ribe SD, Chen A, Hines D, Moussa SH, Carter NM, Sylvester MA, Romero JAC, Vega CV, Sacco MD, Chen Y, O’Donnell JP, Durand-Reville TF, Miller AA and Tommasi RA

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay

Bioorganic and Medicinal Chemistry (2020)

Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O'Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, and Alirol E

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea – challenges and opportunities

Clinical Microbiology and Infection (2020)

Durand-Réville TF, Comita-Prevoir J, Zhang J, Wu X, May-Dracka T, Romero T, Wu F, Chen A, Shapiro AB, Carter N, McLeod S, Giacobbe R, Verheijen J, Lahiri S, Sacco M, Chen Y, O’Donnell J, Miller AA, Mueller JP, and Tommasi R

Discovery of an orally available diazabicyclooctane inhibitor (ETX0282) of class A, C and D serine β-lactamases

Journal of Medicinal Chemistry (2020)

Lickliter JD, Lawrence K, O’Donnell J, and Isaacs R

Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects

Antimicrobial Agents and Chemotherapy (2020)

Seifert H, Muller C, Stefanik D, Higgins PG, Miller A and Kresken M

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy (2020)

O’Donnell J, Tanudra A, Chen A, Hines D, Tommasi R, and Mueller J

Pharmacokinetic/pharmacodynamic determination and preclinical pharmacokinetics of the β-lactamase inhibitor ETX1317 and its orally available prodrug ETX0282

ACS Infectious Diseases (2020)